Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

被引：0

作者：

Li Shen Loo

Jessica Ailani

Jack Schim

Simin Baygani

Hans-Peter Hundemer

Martha Port

John H. Krege

机构：

[1] Lilly Research Laboratories,

[2] Lilly Corporate Center,undefined

[3] MedStar Georgetown University Hospital,undefined

[4] The Neurology Center of Southern California,undefined

[5] Lilly Deutschland GmbH,undefined

[6] Medical Department,undefined

来源：

The Journal of Headache and Pain | 2019年 / 20卷

关键词：

Acute treatment; Concomitant; Ditan; Efficacy; Lasmiditan; Migraine; Migraine medication; Migraine preventive; Migraine prophylaxis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
Zhou, Jiying
Luo, Guogang
Xu, Yuming
Yang, Xiaosu
Pan, Xiaoping
Dong, Zhao
Zhong, Shiying
Liu, Hui
Ji, Fei
Yu, Shengyuan
[J]. ADVANCES IN THERAPY, 2022, 39 (11) : 5229 - 5243
[32] Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
Doty, Erin Gautier
Krege, John H.
Jin, Leah
Raskin, Joel
Singh, Rashmi B. Halker
Kalidas, Kavita
[J]. CEPHALALGIA, 2019, 39 (12) : 1569 - 1576
[33] Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
Ruff, D. D.
Ford, J. H.
Tockhorn-Heidenreich, A.
Stauffer, V. L.
Govindan, S.
Aurora, S. K.
Terwindt, G. M.
Goadsby, P. J.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 609 - 618
[34] Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
Stauffer, Virginia L.
Turner, Ira
Kemmer, Phebe
Kielbasa, William
Day, Kathleen
Port, Martha
Quinlan, Tonya
Camporeale, Angelo
[J]. JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
[35] Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
Virginia L. Stauffer
Ira Turner
Phebe Kemmer
William Kielbasa
Kathleen Day
Martha Port
Tonya Quinlan
Angelo Camporeale
[J]. The Journal of Headache and Pain, 2020, 21
[36] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
Martinez, James M.
Garce, Sandra
Anglin, Greg
Hodsdon, Michael
Kielbasa, William
Moser, Brian A.
Pearlman, Eric
[J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
[37] Safety and Efficacy of Concomitant Erenumab and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients
Ahmed, Zubair
Vann, Robert
Fitzpatrick, Christopher
Ray, Sutapa
Shrewsbury, Stephen
Aurora, Sheena
[J]. NEUROLOGY, 2023, 100 (17)
[38] Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials
Henry, R. R.
Buse, J. B.
Wu, H.
Durrwell, L.
Mingrino, R.
Jaekel, K.
El Azzouzi, B.
Andjelkovic, M.
Herz, M.
[J]. DIABETES OBESITY & METABOLISM, 2015, 17 (06): : 560 - 565
[39] Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
Hutchinson, Susan
Dodick, David W.
Treppendahl, Christina
Bennett, Nathan L.
Yu, Sung Yun
Guo, Hua
Trugman, Joel M.
[J]. NEUROLOGY AND THERAPY, 2021, 10 (01) : 235 - 249
[40] Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
Susan Hutchinson
David W. Dodick
Christina Treppendahl
Nathan L. Bennett
Sung Yun Yu
Hua Guo
Joel M. Trugman
[J]. Neurology and Therapy, 2021, 10 : 235 - 249

← 1 2 3 4 5 →